CN1396453A - Reagent kit for early diagnosis of acute myocardial infarction - Google Patents
Reagent kit for early diagnosis of acute myocardial infarction Download PDFInfo
- Publication number
- CN1396453A CN1396453A CN 02117447 CN02117447A CN1396453A CN 1396453 A CN1396453 A CN 1396453A CN 02117447 CN02117447 CN 02117447 CN 02117447 A CN02117447 A CN 02117447A CN 1396453 A CN1396453 A CN 1396453A
- Authority
- CN
- China
- Prior art keywords
- fabp
- myocardial infarction
- early diagnosis
- acute myocardial
- reagent kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010000891 acute myocardial infarction Diseases 0.000 title claims abstract description 48
- 238000013399 early diagnosis Methods 0.000 title claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 239000000872 buffer Substances 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 28
- 238000000746 purification Methods 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 238000001262 western blot Methods 0.000 claims description 10
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 6
- 210000004989 spleen cell Anatomy 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 238000011725 BALB/c mouse Methods 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 238000013016 damping Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000003757 reverse transcription PCR Methods 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000012407 engineering method Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 abstract description 3
- 238000000576 coating method Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 63
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 58
- 238000002360 preparation method Methods 0.000 description 9
- 238000009413 insulation Methods 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000013394 Troponin I Human genes 0.000 description 3
- 108010065729 Troponin I Proteins 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Abstract
A reagent kit for early diagnosis of acute myocardial infarction contains standard h-FABP protein, monoclonal and polyconal antibodies of h-FABP, their markers, enclosing liquid, enzyme substrate solution, coating buffer, stop buffer, washing liquid and enzyme-linked board. Its advantages are simple operation and high sensitivity and specifity.
Description
Technical field: the present invention relates to the expression of preparation, H-FABP of the antibody (comprise monoclonal antibody and many anti-) of H-FABP (h-FABP) and the technical field of utilizing the antibody of anti-H-FABP to come early diagnosis acute myocardial infarction (AMI), relate in particular to a kind of reagent kit for early diagnosis of acute myocardial infarction.
Background technology: acute myocardial infarction has become the angiocardiopathy that has a strong impact on human health, but it is at present not ideal enough for this sick result of treatment, one of them main cause is to make correct diagnosis in early days in the AMI outbreak, to such an extent as to can not take suitable therapeutic scheme.There is 50% AMI patient dead in preceding 2 hours of morbidity approximately, so, will improve result of treatment greatly and improve cure rate if can make correct diagnosis in early days in the AMI outbreak.Diagnosis AMI mainly measures by Electrocardioscopy and biochemical indicator, but the accuracy rate of Electrocardioscopy has only about 50%, and it is exactly because cardiogram normally and is not diagnosed accurately that similar 30% cardiac is arranged in the world, thereby has incured loss through delay treatment; The biochemical indicator that is used for clinical diagnosis AMI at present is also not ideal enough, they mainly contain creatine kinase isozyme (CK-MB), Troponin I (troponin I), TnT (troponin T) and myoglobins (myoglobin) etc., CK-MB, Troponin I, TnT lack susceptibility to the early diagnosis of AMI, and they are just concentration rising in 6-8 hour after pectoralgia; Myoglobins then lacks specificity, though its 2-3 hour concentration after pectoralgia rises, can not distinguish skeletal muscle and myocardial damage, so press for a kind of new high specific and the biochemical indicator of hypersensitivity comes early diagnosis AMI.Studies show that in a large number H-FABP (h-FABP) concentration in AMI showed effect back 2 hours begins to rise, and single-minded in induced myocardial injury, has high specificity and susceptibility for early diagnosis AMI.
Summary of the invention:
Goal of the invention: the monoclonal antibody and resist as the biochemical indicator of AMI early diagnosis, the easy kit that is easy to get that the purpose of this invention is to provide a kind of h-FABP of utilization and anti-h-FABP more, measure the concentration of the h-FABP in the human serum, to be used for early diagnosis AMI, improve the susceptibility and the specificity of AMI early diagnosis.
Technical scheme:
Reagent kit for early diagnosis of acute myocardial infarction of the present invention comprises standard h-FABP; The monoclonal antibody of anti-h-FABP; The polyclonal antibody of anti-h-FABP; Two anti-labels; Confining liquid; Enzyme substrate solution; Bag is cushioned liquid; Stop buffer; Cleansing solution; ELISA Plate; Wherein the polyclonal antibody bag of anti-h-FABP quilt is in ELISA Plate.
Described h-FABP standard protein adopts gene engineering method to make: the method clone h-FABP gene that utilizes RT-PCR from heart tissue, be inserted on the carrier pET22b (+), after order-checking conclusive evidence gene is correct, be transferred among the E.coli BL21 (DE3) the IPTG abduction delivering; The h-FABP that expresses utilizes Ni-Agarose affinity chromatography column separating purification.
Described anti-h-FABP resists the h-FABP immune rabbit with purifying more, obtains containing the rabbit anteserum of anti-h-FABP antibody; Earlier with (NH
4)
2SO
4The precipitation method are the preliminary purification Immunoglobulin IgG from the serum of rabbit, is further purified the IgG of anti-h-FABP again with homemade h-FABP-Sepharose affinity column, and SDS-PAGE and western blotting identify the how anti-of separation and purification.
Described anti-h-FABP monoclonal antibody obtains the spleen cell of antigenic stimulus with the h-FABP immunity BALB/c mouse of purifying, merges the myeloma cell line P3-X63-Ag8.653 of this spleen cell and mouse; Utilize HAT to select nutrient culture media to select hybridoma, and utilize the ELISA method to identify the cell that produces anti-h-FABP antibody; The cell line of the monoclonal antibody that the generation that preservation is screened combines with the h-FABP high specific; Utilize the cell fermentation device to cultivate the cell line of being preserved, the collecting cell culture supernatant is earlier with (NH
4)
2SO
4The monoclonal antibody of the precipitation method anti-h-FABP of preliminary purification from cells and supernatant, utilize Protein A-Sepharose affinity column to be further purified the monoclonal antibody of anti-h-FABP again from cells and supernatant, SDS-PAGE and westernblotting identify the monoclonal antibody of separation and purification.
Described confining liquid is 1% gelatin solution; Described enzyme substrate solution is that TMB uses liquid, i.e. 60ug/mlTMB, 0.045%H
2O
2In 0.1M pH6.0 phosphate buffer; Bag is cushioned the carbonate buffer solution that liquid is 0.05M pH9.6, promptly contains 1.59 gram Na in 1 liter of solution
2CO
3, 2.93 gram NaHCO
3Stop buffer is 2mol/L H
2SO
4Solution; Cleansing solution is 0.01mol/L pH7.4 phosphate-NaCl damping fluid (PBS), and PBS includes 0.05%Tween-20, promptly contains 8g NaCl in 1 liter of solution, 0.2g KH
2PO
4, 2.9g Na
2HPO
412H
2O, 0.2g KCl, 0.5ml Tween-20.
Inventive principle and good effect analysis:
The present invention be with h-FABP as biochemical indicator, come early diagnosis AMI.This comprises the method for the how anti-and monoclonal antibody of the above-mentioned h-FABP of preparation, and utilizes the ELISA method to measure the concentration of the h-FABP in the serum, with diagnosis AMI.
How anti-the present invention utilize the monoclonal antibody of anti-h-FABP and, wherein utilize how anti-as first antibody, i.e. coated antibody, this has reduced experiment and expends and simplified the experiment operation, has but reached and utilizes two kinds of effects that monoclonal antibody is identical at least; Simultaneously, we utilize engineered method to obtain h-FABP, and with as antigen, this has replaced the method for extracting from patient's cardiac muscle, and material is easy to get and is simple to operate.Utilize the biochemical indicator of h-FABP, improved the susceptibility and the specificity of AMI early diagnosis as the AMI early diagnosis.
The how anti-and monoclonal antibody of the anti-h-FABP of method utilization of the present invention preparation can be after pectoralgia goes out acute myocardial infarction with regard to diagnosable in 2 hours, has higher specificity and susceptibility, has overcome the shortcoming that is used for other clinical biochemical indicators at present.
Experimental result of the present invention and analysis:
1) expression of h-FABP and purifying: the h-FABP gene clone is gone up and is transferred among the E.coli BL21 (DE3) to expression vector pET22b (+), and IPTG abduction delivering, h-FABP are expressed in E.coli BL21 (DE3); Utilize Ni-Agarose affinity column separation and purification h-FABP from the lysate of E.coli, identify that through SDS-PAGE a protein band (Fig. 1) is arranged at the 18kD place; Utilize the antibody of anti-h-FABP to carry out immuning hybridization, find only to have at the 18kD place hybridization band (Fig. 2), this shows that resulting albumen is h-FABP.H-FABP is the micromolecule of 15kD in the heart, the present invention is expressed in E.coli, the h-FABP of purifying is 18kD, this is because its N end has a segment signal peptide, the C end has 6xHis-tag, these two sections sequences are that expression vector pET22b (+) has, h-FABP in the serum does not then have this sequence, but since the antibody of the anti-h-FABP of separation and purification of the present invention special antigenic determinant be the sequence antigenic determinant, so h-FABP in the h-FABP of this reorganization and the combination of antibody and the serum and antibody in conjunction with consistent, do not influence experimental result.The present invention utilizes engineered method to prepare h-FABP, thus replaced from cardiac muscle separation and purification h-FABP method, this not only draws materials easily, and has simplified operating process, it is expensive to have saved experiment.
2) preparation of the antibody of anti-h-FABP and purifying:
I) preparation of the monoclonal antibody of anti-h-FABP and purifying the present invention have prepared the monoclonal antibody IgG of high specific and affinity, and utilize (NH
4)
2SO
4The precipitation method and the separation and purification from the culture supernatant of hybridoma of Protein A-Sepharose affinity column obtain the antibody of pure anti-h-FABP, and SDS-PAGE identifies at 55kD and 24kD place two protein bands are arranged, and is heavy chain and the light chain of IgG; Simultaneously, identify that through WesternBlotting this IgG can be hybridized with h-FABP, the resulting IgG of this explanation separation and purification is the antibody that is specific to h-FABP.
Ii) the how anti-preparation of anti-h-FABP and purifying the present invention have prepared high tire how anti-, and utilize (NH
4)
2SO
4The separation and purification from the serum of rabbit of the precipitation method and h-FABP-Sepharose affinity column has gone out the antibody of the anti-h-FABP of high specific and affinity, and SDS-PAGE identifies at 55kD and 24kD place two protein bands are arranged, and is heavy chain and the light chain of IgG; Simultaneously, identify that through Western Blotting this IgG can be hybridized with h-FABP, the resulting IgG of this explanation separation and purification is the antibody that is specific to h-FABP.
3) ELISA detects the concentration of h-FABP in the different blood samples, to diagnose AMI: utilize the how anti-and monoclonal antibody of prepared anti-h-FABP, adopt sandwich style ELISA method, measure the concentration of the h-FABP in the different serum.Detected the concentration of h-FABP in 126 normal persons, 41 patients with coronary heart disease and 33 AMI patients' the serum altogether, and AMI patient's blood sample is from falling ill back 1 hour to 24 hours, got one time blood in average per 2 hours.By measurement result as seen, 1) h-FABP began to rise in 2 hours among the AMI patients serum, reached mxm. in 5-6 hour, returned to the normal level (see figure 3) in 12-24 hour; 2) the h-FABP concentration in normal person and the patients with coronary heart disease serum is close, and is starkly lower than AMI patient's h-FABP concentration (seeing Table 1); 3) according to the h-FABP concentration in the normal human serum, utilize the algorithm of mean value+2 times variance, trying to achieve and diagnosing the cutoff value (cut off value) of biochemical indicator with h-FABP as AMI is 7.543ng/ml.In addition, the present invention resists as first antibody with more, and as second antibody, this has obtained and the identical even better effect of the external method of reporting of utilizing two kinds of monoclonal antibodies with monoclonal antibody, but simple, the easy row of method of the present invention, expensive lacking.
The mean intensity value of h-FABP among table 1 normal person, patients with coronary heart disease and the AMI patients serum
| Mean value (ng/ml) | Variance | |
| The normal person | ????2.791 | ????2.376 |
| Patients with coronary heart disease | ????4.268 | ????2.045 |
| AMI patient | ????84.453 | ????85.805 |
Annotate: every duplicate samples is all surveyed three times. average
Description of drawings:
Fig. 1 SDS-PAGE (12%) identifies expression, the purified condition synoptic diagram of h-FABP
1. protein molecular weight marker, molecular weight is respectively from big to small: 97 000Da, 66 000Da, 43000 Da, 31 000Da, 20 100Da, 14 400Da.
2. the h-FABP sample behind Ni-Agarose affinity chromatography column separating purification
Fig. 2 Western-Blotting further identifies expression, the purified condition synoptic diagram of h-FABP
1. protein molecular weight marker, molecular weight is respectively from big to small: 97 000Da, 66 000Da, 43 000Da, 31 000Da, 20 100Da, 14 400Da.
2. the h-FABP sample behind Ni-Agarose affinity chromatography column separating purification
Fig. 3 AMI patient concentration change of h-FABP in the different time serum after morbidity
Annotate: the numerical value among the figure is the mean value of 33 AMI patients' h-FABP concentration value
Embodiment:
1. clone, expression, purifying and identify h-FABP:
From Gene Bank seeker's h-FABP gene, be according to the gene order design primer that is searched: 5 '-AGCTGGATCCATGGTGGACGCTTTCCTGGGC-3 '
5′-CTAGGAATTCTGCCTCTTTCTCATAAGTGCG-3′
From heart tissue, utilize the method clone h-FABP gene of RT-PCR then, enzyme by routine is cut, is connected the equimolecular biologic operation resulting h-FABP gene is inserted on the carrier pET22b (+), after order-checking conclusive evidence gene is correct, prokaryotic expression carrier pET22b (+)-hFABP that obtains recombinating utilizes CaCl
2The method that transforms is transferred to this recombinant vector in E.coli BL21 (DE3) competent cell, utilize the IPTG abduction delivering, the h-FABP that expresses utilizes Ni-Agarose affinity chromatography column separating purification, and SDS-PAGE and western blotting identify the h-FABP of separation and purification.
2. preparation, purifying and identify the antibody of anti-h-FABP:
I) preparation, purifying and the monoclonal antibody of identifying anti-h-FABP utilize lumbar injection method immunity BALB/c mouse with the h-FABP of purifying, and every three all immunity once, immunity is four times altogether; Take out the spleen cell of immune mouse then, utilize PEG-4000 to merge the myeloma cell line P3-X63-Ag8.653 of this spleen cell and mouse; Utilize HAT to select nutrient culture media on 96 porocyte culture plates, to select hybridoma, and utilize the ELISA method to identify the cell that produces anti-h-FABP antibody; The cell line of the monoclonal antibody that the generation that preservation is screened combines with the h-FABP high specific; Utilize the cell fermentation device to cultivate the cell line of being preserved, the collecting cell culture supernatant is earlier with (NH4)
2SO
4The monoclonal antibody of the precipitation method anti-h-FABP of preliminary purification from cells and supernatant, utilize Protein A-Sepharose affinity column to be further purified the monoclonal antibody of anti-h-FABP again from cells and supernatant, SDS-PAGE and western blotting identify the monoclonal antibody of separation and purification.
Ii) preparation, purifying and the how anti-h-FABP immune rabbit of identifying anti-h-FABP with purifying, immunity twice, one month at interval; Get the whole blood of rabbit.Earlier with (NH4)
2SO
4The precipitation method are the preliminary purification Immunoglobulin IgG from the serum of rabbit, is further purified the IgG of anti-h-FABP again with homemade h-FABP-Sepharose affinity column, and SDS-PAGE and western blotting identify the how anti-of separation and purification.
3.ELISA the h-FABP concentration in the mensuration serum is with diagnosis AMI:1) compound method of various damping fluids and reagent:
I) bag is cushioned liquid: the Na of 0.05M pH9.6
2CO
3-NaHCO
3
Na2CO
3(MW 105.99) 1.59 grams
NaHCO
3(MW 84.01) 2.93 grams
Distill water-soluble to 1000mlii) PBS-Tween 20 of cleansing solution: pH7.4
NaCl (MW 58.44) 8.0 grams
KH
2PO
4(MW 136.09) 0.2 gram
Na
2HPO
412H
2O (MW 358.14) 2.9 grams
(perhaps NaHPO
41.14 gram)
KCl (MW 74.56) 0.2 gram
Tween?20????????????????????0.5ml
Distill water-soluble to 1000mliii) confining liquid: 1% gelatin solution
Gelatin 1 gram
Cleansing solution is molten to 100mliv) enzyme substrate solution: TMB (3,3 ', 5,5 ' tetramethyl is for biphenylamine) application liquid
A.0.1M pH6.0 phosphate buffer
NaHPO
42H
2O 1.09 grams
NaH
2PO
4H
2O 6.05 grams
Distill water-soluble to 500ml
B.TMB stores liquid
60 milligrams of TMB
DMSO is molten to 10ml
4 ℃ of storages
C.TMB uses liquid
Phosphate buffer 1 0ml
TMB storage liquid 100ul
30％H
2O
2???????????????15ul
(face with preceding and now join) be stop buffer v): 2M H
2SO
4
The concentrated sulphuric acid (95%-98%) 22.2ml
Distilled water 177.3ml
(timing slowly splashes into the concentrated sulphuric acid in the distilled water, limit edged mixing) 2) operation steps i) the formulation typical curve is diluted to 1ug/ml with the how anti-solution of anti-h-FABP of purifying with coating buffer, join in the 96 hole ELISA Plate, every hole 100ul, 37 ℃ of bags were spent the night by 2 hours or 4 ℃; Cleansing solution is washed plate 3 times, dries, and adds the sealing of 1% gelatin, every hole 200ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds h-FABP (0-20ng/ml) standard antigen of variable concentrations, every hole 100ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds anti-h-FABP monoclonal antibody solution (being diluted to 1ug/ml with cleansing solution), every hole 100ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds two anti-solution (with cleansing solution dilution in 1: 1000), every hole 100ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds enzyme substrate solution, every hole 100ul, and dark place colour developing 5 minutes adds stop buffer, and every hole 50ul utilizes microplate reader to measure absorbance value (A at 450nm
450nm); With concentration (ng/ml) is horizontal ordinate, A
450nmBe ordinate, the drawing standard curve.Ii) measure the h-FABP concentration in the serum:
The how anti-solution of anti-h-FABP of purifying is diluted to 1ug/ml with coating buffer, joins in the 96 hole ELISA Plate, every hole 100ul, 37 ℃ of bags were spent the night by 2 hours or 4 ℃; Cleansing solution is washed plate 3 times, dries, and adds the sealing of 1% gelatin, every hole 200ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds the serum of suitable multiple dilution, every hole 100ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds anti-h-FABP monoclonal antibody solution (being diluted to 1ug/ml with cleansing solution), every hole 100ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds two anti-solution (with cleansing solution dilution in 1: 1000), every hole 100ul, room temperature insulation 2 hours; Cleansing solution is washed plate 3 times, dries, and adds enzyme substrate solution, every hole 100ul, and dark place colour developing 5 minutes adds stop buffer, and every hole 50ul utilizes microplate reader to measure absorbance value (A at 450nm
450nm); According to typical curve, by measured A
450nmTry to achieve the concentration value of h-FABP in the serum.Iii) the result judges that the decidable that concentration is higher than this value is acute myocardial infarction according to cutoff value (the cut off value) 7.543ng/ml of h-FABP as the acute myocardial infarction diagnosis index, and what be lower than this value then is not acute myocardial infarction.
Claims (9)
1, a kind of reagent kit for early diagnosis of acute myocardial infarction comprises standard h-FABP albumen; The monoclonal antibody of anti-h-FABP; The polyclonal antibody of anti-h-FABP; Two anti-labels; Confining liquid; Enzyme substrate solution; Bag is cushioned liquid; Stop buffer; Cleansing solution; ELISA Plate; How anti-bag quilt is in ELISA Plate for wherein anti-h-FABP.
2, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1, it is characterized in that described h-FABP standard protein adopts gene engineering method to make: the method clone h-FABP gene that from heart tissue, utilizes RT-PCR, be inserted on the carrier pET22b (+), after order-checking conclusive evidence gene is correct, be transferred among the E.coli BL21 (DE3) the IPTG abduction delivering; The h-FABP that expresses utilizes Ni-Agarose affinity chromatography column separating purification.
3, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1, it is characterized in that the h-FABP immunity BALB/c mouse of described anti-h-FABP monoclonal antibody with purifying, obtain the spleen cell of antigenic stimulus, merge the myeloma cell line P3-X63-Ag8.653 of this spleen cell and mouse; Utilize HAT to select nutrient culture media to select hybridoma, and utilize the ELISA method to identify the cell that produces anti-h-FABP antibody; The cell line of the monoclonal antibody that the generation that preservation is screened combines with the h-FABP high specific; Utilize the cell fermentation device to cultivate the cell line of being preserved, the collecting cell culture supernatant is earlier with (NH
4)
2SO
4The monoclonal antibody of the precipitation method anti-h-FABP of preliminary purification from cells and supernatant, utilize Protein A-Sepharose affinity column to be further purified the monoclonal antibody of anti-h-FABP again from cells and supernatant, SDS-PAGE and western blotting identify the monoclonal antibody of separation and purification.
4, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1 is characterized in that described anti-h-FABP resists the h-FABP immune rabbit with purifying more, obtains containing the rabbit anteserum of anti-h-FABP antibody; Earlier with (NH
4)
2SO
4The precipitation method are the preliminary purification Immunoglobulin IgG from the serum of rabbit, is further purified the IgG of anti-h-FABP again with homemade h-FABP-Sepharose affinity column, and SDS-PAGE and westernblotting identify the how anti-of separation and purification.
5, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1 is characterized in that described confining liquid is 1% gelatin solution.
6, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1 is characterized in that described enzyme substrate solution is 60ug/ml TMB, 0.045%H
2O
2In 0.1M pH6.0 phosphate buffer.
7, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1 is characterized in that described bag is cushioned the carbonate buffer solution that liquid is 0.05M pH9.6, promptly contains 1.59 gram Na in 1 liter of solution
2CO
3, 2.93 gram NaHCO
3
8, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1 is characterized in that described stop buffer is 2mol/L H
2SO
4Solution.
9, reagent kit for early diagnosis of acute myocardial infarction as claimed in claim 1 is characterized in that described cleansing solution is 0.01mol/L pH7.4 phosphate-NaCl damping fluid, and PBS includes 0.05%Tween-20, promptly contains 8g NaCl in 1 liter of solution, 0.2g KH
2PO
4, 2.9g Na
2HPO
412H
2O, 0.2g KCl, 0.5ml Tween-20.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02117447 CN1219215C (en) | 2002-05-17 | 2002-05-17 | Reagent kit for early diagnosis of acute myocardial infarction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02117447 CN1219215C (en) | 2002-05-17 | 2002-05-17 | Reagent kit for early diagnosis of acute myocardial infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1396453A true CN1396453A (en) | 2003-02-12 |
| CN1219215C CN1219215C (en) | 2005-09-14 |
Family
ID=4744429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02117447 Expired - Lifetime CN1219215C (en) | 2002-05-17 | 2002-05-17 | Reagent kit for early diagnosis of acute myocardial infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1219215C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102358895A (en) * | 2011-10-28 | 2012-02-22 | 南京医科大学第一附属医院 | Monoclonal antibody mcf2 and application thereof |
| CN102399752A (en) * | 2011-10-28 | 2012-04-04 | 南京医科大学第一附属医院 | Heart type-fatty acid binding protein monoclonal antibody mcf1 and application thereof |
| CN102628864A (en) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | Kit for determining heart-type fatty acid binding protein in serum or urine by latex enhanced turbidimetric immunoassay |
| CN102735849A (en) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | Enzymatic chemiluminescence immunoassay method for human heart-type fatty acid binding protein and reagent kit |
| CN111505303A (en) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | Kit for detecting heart-type fatty acid binding protein by chemiluminescence method and use method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105203770B (en) * | 2015-07-27 | 2017-11-07 | 深圳大学 | Application of the STIM1 albumen in relevant disease diagnosis of risk |
-
2002
- 2002-05-17 CN CN 02117447 patent/CN1219215C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102358895A (en) * | 2011-10-28 | 2012-02-22 | 南京医科大学第一附属医院 | Monoclonal antibody mcf2 and application thereof |
| CN102399752A (en) * | 2011-10-28 | 2012-04-04 | 南京医科大学第一附属医院 | Heart type-fatty acid binding protein monoclonal antibody mcf1 and application thereof |
| CN102399752B (en) * | 2011-10-28 | 2012-10-24 | 杨笛 | Heart type-fatty acid binding protein monoclonal antibody mcf1 and application thereof |
| CN102628864A (en) * | 2011-12-30 | 2012-08-08 | 北京九强生物技术股份有限公司 | Kit for determining heart-type fatty acid binding protein in serum or urine by latex enhanced turbidimetric immunoassay |
| CN102628864B (en) * | 2011-12-30 | 2014-08-13 | 北京九强生物技术股份有限公司 | Kit for determining heart-type fatty acid binding protein in serum or urine by latex enhanced turbidimetric immunoassay |
| CN102735849A (en) * | 2012-07-05 | 2012-10-17 | 北京源德生物医学工程有限公司 | Enzymatic chemiluminescence immunoassay method for human heart-type fatty acid binding protein and reagent kit |
| CN111505303A (en) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | Kit for detecting heart-type fatty acid binding protein by chemiluminescence method and use method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1219215C (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seligmann et al. | Immunochemical studies in four cases of alpha chain disease | |
| CN102175875B (en) | Detection kit for diagnosing tuberculosis | |
| CN101441219A (en) | Coronary heart disease and palsy risk diagnosis reagent kit and manufacturing method thereof | |
| CN1861632A (en) | Coupling compound of Norfloxacin, preparation process and application thereof | |
| CN103045541A (en) | Hybridoma cell strain and monoclonal antibody of anti-heart-type fatty acid-binding protein generated by same | |
| CN102703388A (en) | Anti-human mCRP (monomeric C-reaction protein) monoclonal antibody, hybridoma cell lines and kit | |
| CN102351947B (en) | Ev71 early diagnosis method and reagent kit | |
| CN1219215C (en) | Reagent kit for early diagnosis of acute myocardial infarction | |
| CN1904616A (en) | Early stage predetection acute coronary comprehensive diagnosis kit | |
| JP5054426B2 (en) | Anti-β-1,3-glucan monoclonal antibody | |
| Kronenberg et al. | Serological Assays for Alveolar and Cystic Echinococcosis—A Comparative Multi-Test Study in Switzerland and Kyrgyzstan | |
| CN103074303A (en) | Hybridoma cell strain generating anti-human NGAL specific monoclonal antibody, monoclonal antibody generated by same and application | |
| CN101109753A (en) | Method for detecting colon bacillus shiga toxin with colloidal gold immune chromatography experiment | |
| CN107561289B (en) | The double crush syndrome detection kit of human cardiac troponin I | |
| CN102608332B (en) | Enzyme-linked immunoassay (ELISA) method of grass carp interleukin 10 | |
| JP5054425B2 (en) | Anti-β-1,6-glucan monoclonal antibody | |
| CN102539767B (en) | ELISA (Enzyme-Linked Immunosorbent Assay) kit for detecting polypeptide marker antigen | |
| CN105606814A (en) | Fluorescence immune chromatography test paper for detecting human ApoE-[epsilon]4 protein and preparation method thereof | |
| CN1644685A (en) | Monoclone antibody against human cardiac troponin I and its use | |
| CN102401831A (en) | Competitive enzyme-linked immunosorbent assay kit for liver cirrhosis and assay method for competitive enzyme-linked immunosorbent assay kit | |
| CN102174114B (en) | Whole blood INF-gamma specific antigen protein and preparation method and application thereof | |
| CN102040660A (en) | Recombinant protein as BNP (Brain Natriuretic Peptide) immunodiagnostic reagent standard as well as preparation method and application thereof | |
| CN102520175B (en) | Competitive enzyme-linked immunosorbent assay (ELISA) kit for liver cancer polypeptide marker antigen | |
| CN1827643A (en) | Danofloxacin couple and its preparing method and use | |
| CN1952136A (en) | Gene expression product of extro-cellular domain carboxyl end of human thyrotropin receptor, its preparing method and application in enzyme immune technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HU MEIHAO Free format text: FORMER NAME OR ADDRESS: HU MEIHAO; XIE YONG |
|
| CP03 | Change of name, title or address |
Address after: 100080 No. 45 apartment 102, Guan garden, Peking University, Beijing, Haidian District Patentee after: Hu Meihao Address before: 100080 No. 45 apartment 102, Guan garden, Peking University, Beijing, Haidian District Co-patentee before: Xie Yong Patentee before: Hu Meihao |
|
| ASS | Succession or assignment of patent right |
Owner name: LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS Free format text: FORMER OWNER: HU MEIHAO Effective date: 20080815 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080815 Address after: Gansu province Lanzhou City plant No. 888 Patentee after: Lanzhou Inst. of Biological Products Address before: No. 45 apartment 102, Guan garden, Peking University, Beijing, Haidian District Patentee before: Hu Meihao |
|
| C56 | Change in the name or address of the patentee |
Owner name: LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD. Free format text: FORMER NAME: LANZHOU INST. OF BIOLOGICAL PRODUCTS |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 730046 Gansu province Lanzhou City saltern No. 888 Patentee after: Lanzhou Institute of Biological Products Co., Ltd. Address before: 730046 Gansu province Lanzhou City saltern No. 888 Patentee before: Lanzhou Inst. of Biological Products |
|
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 730046 Gansu province Lanzhou City saltern Road No. 888 Patentee after: Lanzhou Institute of Biological Products Co., Ltd. Address before: 730046 Gansu province Lanzhou City saltern No. 888 Patentee before: Lanzhou Institute of Biological Products Co., Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050914 |